Vijayagopal P, Srinivasan S R, Radhakrishnamurthy B, Berenson G S
Department of Medicine, Louisiana State University Medical Center, New Orleans 70112.
Biochem J. 1993 Feb 1;289 ( Pt 3)(Pt 3):837-44. doi: 10.1042/bj2890837.
We have shown recently that lipoprotein-proteoglycan complexes isolated from human atherosclerotic lesions stimulated cholesteryl ester synthesis in human monocyte-derived macrophages [Vijayagopal, Srinivasan, Radhakrishnamurthy and Berenson (1992) Arterioscler. Thromb. 12, 237-249]. The present study was conducted to determine the mechanism of cellular uptake of the complexes. A chondroitin sulphate-dermatan sulphate proteoglycan was isolated from normal human aorta and complexed to 125I-labelled human low-density lipoprotein (LDL). The binding and degradation of 125I-LDL-proteoglycan complex were then studied in human monocyte-derived macrophages. The specific binding and degradation of the complex showed saturability and concentration-dependency. The Kd for binding was 1.5 x 10(-8) M, which was greater than that reported for LDL in monocyte-derived macrophages. Binding of the complex was not subject to down-regulation. Chloroquine inhibited degradation of the complex and the resultant stimulation of cholesteryl ester synthesis. Limited treatment of macrophages with proteolytic enzymes abolished binding and degradation of the complex significantly. Macrophages bound 125I-methyl-LDL-proteoglycan complex to the same extent as 125I-LDL-proteoglycan complex. Excess LDL and proteoglycan did not compete against the binding of the complex; however, excess acetyl-LDL competed for 61% of the binding. Likewise, excess LDL-proteoglycan complex inhibited the binding of 125I-acetyl-LDL by 64%. Polyinosinic acid and cytochalasin D inhibited the binding of 125I-LDL-proteoglycan complex by 60% and 36% respectively. Compared with that of acetyl-LDL, the degradation of LDL-proteoglycan complex was retarded in human macrophages. The results indicate that the uptake of LDL-proteoglycan complex in human monocyte-derived macrophages is not mediated through binding to the LDL receptor; but occurs predominantly via the scavenger receptor, with phagocytosis playing a minor role in the process.
我们最近发现,从人类动脉粥样硬化病变中分离出的脂蛋白 - 蛋白聚糖复合物可刺激人类单核细胞衍生巨噬细胞中的胆固醇酯合成[Vijayagopal, Srinivasan, Radhakrishnamurthy和Berenson(1992年),《动脉硬化血栓形成》12卷,237 - 249页]。本研究旨在确定该复合物细胞摄取的机制。从正常人主动脉中分离出硫酸软骨素 - 硫酸皮肤素蛋白聚糖,并与125I标记的人低密度脂蛋白(LDL)复合。然后在人类单核细胞衍生巨噬细胞中研究125I - LDL - 蛋白聚糖复合物的结合和降解。该复合物的特异性结合和降解表现出饱和性和浓度依赖性。结合的解离常数(Kd)为1.5×10(-8)M,高于单核细胞衍生巨噬细胞中报道的LDL的Kd值。该复合物的结合不受下调调节。氯喹抑制该复合物的降解以及由此产生的胆固醇酯合成刺激。用蛋白水解酶对巨噬细胞进行有限处理可显著消除该复合物的结合和降解。巨噬细胞对125I - 甲基 - LDL - 蛋白聚糖复合物的结合程度与对125I - LDL - 蛋白聚糖复合物的结合程度相同。过量的LDL和蛋白聚糖不会与该复合物的结合竞争;然而,过量的乙酰化LDL可竞争61%的结合。同样,过量的LDL - 蛋白聚糖复合物可抑制125I - 乙酰化LDL的结合达64%。聚肌苷酸和细胞松弛素D分别抑制125I - LDL - 蛋白聚糖复合物的结合达60%和36%。与乙酰化LDL相比,LDL - 蛋白聚糖复合物在人类巨噬细胞中的降解受到延迟。结果表明,人类单核细胞衍生巨噬细胞中LDL - 蛋白聚糖复合物的摄取不是通过与LDL受体结合介导的;而是主要通过清道夫受体发生,吞噬作用在该过程中起次要作用。